非小细胞肺癌治疗新焦点：PD-1/PD-L1应用进展

PD-1/PD-L1 Pathway in Non-small Cell Lung Cancer: What Achieves So Far?

摘要: 程序性细胞死亡因子1（PD-1）是由PDCD-1基因编码的一种表达在T细胞细胞膜和细胞质中的抑制性受体。PD-1及其配体PD-L1（B7-H1/CD274）、PD-L2(B7-DC/CD273)在调节免疫反应和维持外周免疫耐受中具有重要作用。PD-1/PD-L1通过抑制T淋巴细胞增殖、存活和效应功能诱导抗原特异性T细胞凋亡，促进CD4⁺T细胞向Foxp3+调节性T细胞分化从而促进肿瘤的发生发展。抗PD-1单克隆抗体（BMS-936558等）及抗PD-L1单克隆抗体（BMS-936559等）的安全性及临床疗效的研究为非小细胞肺癌的治疗带来了新突破，免疫靶向治疗将会成为其治疗的新方向。

Abstract: Programmed cell death factor 1(PD-1) which is expressed in cell membrane and cytoplasm is coded by PDCD-1 gene. It is a kind of T cell inhibitory receptors. PD-1 and its ligands PD-L1(B7-H1/ CD274), PD-L2(B7-DC/CD273) play an important role in regulating immune responses and maintaining of peripheral immune tolerance. PD-1/PD-L1 pathway promotes the development of tumor by inhibiting T lymphocyte proliferation, survival, and function, inducing the antigen specific T cell apoptosis, and promoting CD4+ T cells differentiation to Foxp3⁺ regulatory T cells. The research of the monoclonal antibodies against PD-1(BMS-936558 etc.) and the monoclonal antibodies of PD-L1 (BMS-936559 etc.) have brought a promising future for the treatment of non-small cell lung cancer(NSCLC).